PD-1 inhibitors Highly Effective for Colorectal Cancer in Lynch Syndrome Patients
Written By : Aditi
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2023-08-03 14:30 GMT | Update On 2023-08-04 06:21 GMT
Advertisement
Research article published in the European Journal of Cancer has concluded that Programmed death-1 inhibitors are highly effective for colorectal cancer in patients with a history of Lynch syndrome. Further the researchers found that PD-1 inhibitors were highly effective for deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H) LS CRCs. The 3-year OS and PFS reported with PD-1 inhibitors was 91.2% & 82.2%, respectively. Anti-PD-1 treatment was effective in patients with large LS adenomas (≥7mm).
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.